Semax stroke models measure brain injury, cell signals and behavior after blocked blood flow. Animal and cell results do not prove benefit in people.

Stroke research models test whether Semax changes brain injury, cell signals, or function after blood flow is blocked. They can show effects under set lab conditions, but cell and animal findings do not prove benefit in people.

Semax is a synthetic peptide, or short chain of amino acids, based on the ACTH(4-10) fragment. ACTH means adrenocorticotropic hormone, a hormone made by the body. The peptide's design comes from this short hormone segment, with changes intended to improve its stability.
Studies may examine nerve-supporting proteins, inflammation, and neurotransmission, the signals nerve cells use to communicate. These measures can suggest a possible pathway, but they do not prove that brain injury fell or function improved. Changes in cell signals alone do not show which receptor, if any, Semax binds to or which route it uses.
The site's Semax listing describes a synthetic peptide derived from ACTH(4-10), modified for stability, and marked for research use only. The linked research-use policy provides the site's stated use terms.
Ischemic stroke begins when blood flow to part of the brain is blocked. Cerebral ischemia means reduced blood flow in brain tissue. A common rodent model uses a thin filament to block the middle cerebral artery, a major vessel that supplies part of the brain.

In a temporary blockage model, researchers remove the filament so blood flow can return. This return is called reperfusion. A permanent blockage model keeps the artery blocked, so it does not test the same process as ischemia followed by reperfusion.
A review in The Open Neurology Journal describes transient filament blockage periods usually between 30-120 min before removal allows tissue reperfusion. The length of blockage is one detail that can shape the injury in a given model.
The affected brain area and pattern of injury depend on how the blockage is made. Each method models a different pattern of ischemic injury, so evidence from one method does not establish Semax's effect in another.
An embolic model creates a blockage with particles placed in a brain artery. Particle size and where particles lodge affect which vessels lose blood flow and which brain areas are affected.
The Open Neurology Journal describes animal models that place synthetic macrospheres 300-400 µm in diameter or microspheres less than 50 µm into the internal carotid artery.
Cell models test how cells respond to stress such as low oxygen. They can help isolate direct cell effects, but they do not include blood flow through a whole brain or measure behavior.
| Model | How injury starts | Blood flow after blockage | What it can examine |
|---|---|---|---|
| Temporary filament | Thread blocks an artery | Returns after removal | Blockage and reperfusion |
| Permanent blockage | Artery stays blocked | Does not return in the model | Ongoing loss of blood flow |
| Embolic particles | Particles lodge in vessels | Varies by particle pattern | Vessel blockage patterns |
| Cell model | Cells face low oxygen or other stress | No whole-brain blood flow | Direct cell responses |
These models answer different questions. A cell result, a temporary blockage result, a permanent blockage result, and an embolic result should be read as separate evidence, not as interchangeable tests of Semax.
The start time changes what an experiment can show. Treatment before blockage tests a different question from treatment that begins after blockage or after blood flow returns.

Reports need to state the route, amount, repeat exposure, and time between treatment and measurement. These details shape how much peptide reaches the study system and when researchers assess its effects. For comparisons, check whether timing is anchored to artery blockage or to restored flow; those are different treatment windows.
Peptides are short chains of amino acids, and the body can break them down over time. A peptide's half-life is the time it takes for its amount in the body to fall by half.
Lab teams can make synthetic peptides by joining amino acids in a set order, often on a solid support. Changes to the chain can affect its stability, but greater stability in a lab test does not prove longer action in people.
Researchers may measure damaged brain tissue, cell death, and movement or behavior. Tissue measures show injury at a set time, while repeated behavior tests can track function over time.
Gene expression means which genes are active in a sample. Transcriptomic analysis, a broad test of RNA messages from many genes, can compare gene activity after ischemia.
Neurotrophins are proteins that support nerve cells. Studies may also assess inflammatory signals and neurotransmission to see how cell activity changes after brain injury.
Markers such as pCREB and pJNK are measures of cell signaling. pCREB is a form of a gene-control protein, and pJNK is a form of a stress-signal protein. A shift in either marker alone does not show better movement or lasting recovery.
The Genes report describes a Semax experiment using permanent middle cerebral artery occlusion in rats, with gene-expression measurements at early and later post-occlusion points. Its genome-wide results include transcript changes related to immune response, vascular processes, and calcium signaling. These are associations in sampled tissue, not proof that Semax directly caused each change or that any change reduced injury. The authors note that functions of many affected genes and the causal mechanisms remain uncertain; molecular signals therefore need to be interpreted alongside tissue damage and behavior, not as substitutes for those outcomes.
To judge a reported animal result, readers need the model, treatment route, start time, and measured outcome. A smaller damaged area or a better task score would apply to that setup and follow-up period, not to every stroke model.
An animal model can test a defined question about brain injury, cell activity, or behavior. Its findings may support further study of a possible neuroprotective effect, meaning an effort to limit nerve tissue injury, but they do not prove benefit in people.

The linked Genes report is preclinical, not a human stroke study, so it cannot establish patient outcomes. For a human Semax report, check who took part, when treatment began relative to acute care, what comparison was used, and whether function and safety were followed over time; a marker change alone is not evidence of improved recovery.
Age, sex, other health conditions, and other stroke treatments can affect how well an animal model reflects human stroke. A result in one group of animals may not hold across groups or clinical settings.
A molecular change is not the same as meaningful recovery. Stronger evidence would come from well-controlled human studies that measure lasting function and safety.
Clear reports should name the stroke model, the brain area affected, whether blood flow returned, and the exact treatment route and timing. This detail lets readers compare studies on the same terms.
Studies should include more than one age and sex, and should test health conditions common in stroke. They should also report other treatments given alongside Semax, since these can affect the results.
Repeating a finding in different models can show whether it depends on one setup or appears across distinct kinds of ischemia. Similar results across models would still need direct testing in people.
Researchers should pair tissue and gene measures with repeated function tests. This helps separate early injury from lasting changes in movement or other functions.
These models can show how a peptide relates to measured cell signals, tissue injury, and behavior under defined conditions. The model, treatment timing, route, and outcome all shape what a finding means. Animal and cell results can guide further study, but only well-designed human evidence can establish whether the findings matter for lasting function and safety.